Antitumor agent for thyroid cancer
The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient.
1. A method for treating at least one disease selected from the group consisting of multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract, the method comprising the step of administering an effective amount of an RET kinase inhibiting substance to a patient in need thereof, wherein said RET kinase inhibiting substance is
4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof.
2. The method according to claim 1 , wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
3. A method for treating thyroid carcinoma, comprising administering an effective amount of an RET kinase inhibiting substance to a patient in need thereof, wherein said RET kinase inhibiting substance is
4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
or a pharmacologically acceptable salt thereof.
4. The method according to claim 3 , wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
5. A method for treating a disease, comprising the step of administering an effective amount of an RET kinase inhibiting substance to an organism comprising a cell expressing mutant RET, wherein said RET kinase inhibiting substance is
4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof.
6. The method according to claim 5 , wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.